May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intraocular pharmacokinetics of triamcinolone acetonide after intravitreal and posterior sub–Tenon’s capsule injections
Author Affiliations & Notes
  • M. Nozaki
    Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • K. Okabe
    Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • J. Okabe
    Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Y. Ogura
    Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Footnotes
    Commercial Relationships  M. Nozaki, None; K. Okabe, None; J. Okabe, None; Y. Ogura, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1920. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Nozaki, K. Okabe, J. Okabe, Y. Ogura; Intraocular pharmacokinetics of triamcinolone acetonide after intravitreal and posterior sub–Tenon’s capsule injections . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1920.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Intravitreal and posterior sub–Tenon’s capsule injections of triamcinolone acetonide (TA) have been reported to resolve macular edema and to improve the vision. We comparatively studied the intraocular pharmacokinetics of TA after intravitreal, posterior sub–Tenon’s capsule, and the simultaneous injections of the both routes. Methods: The pigment rabbits were first divided into 2 groups. Rabbits in the group A (n=48) were treated by the injection of TA without vitrectomy and rabbits in the group B (n=36) were received gas vitrectomy before the treatment. TA was administered in the 3 ways; 1) 4 mg–intravitreal injection, 2) 20 mg–posterior sub–Tenon’s capsule injection and 3) simultaneous administration of the both 4 mg–intravitreal injection and 20 mg–posterior sub–Tenon’s capsule injection ("sandwich" injection). Four rabbits each were sacrificed at the intervals ranging from one day to 8 weeks. The vitreous, retina–choroid and aqueous humor were sampled and processed for high–performance liquid chromatography (HPLC) analysis to determine the concentrations of TA. Results: In the non–vitrectomized eyes (group A), the concentrations of TA in the retina–choroid were higher in the "sandwich" injection group than in the intravitreal injection group at 8 weeks. Fifteen percent of TA was remained in the vitreous at 8 weeks in the intravitreal injection group and the "sandwich" injection group. In the vitrectomized eyes (group B), only 7 % of TA was remained in the both groups at 8 weeks. Conclusions: These results suggested that TA "sandwich" injection maintains higher concentrations in the retina–choroid than the intravitreal injection for the long period. Although the clearance of TA from the vitreous cavity was faster in the vitrectomized eyes, there was no significant difference between the non–vitrectomized and the vitrectomized eyes in the concentrations of retina–choroid with these doses of TA.

Keywords: corticosteroids • drug toxicity/drug effects • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×